Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Investor Presentation (May 2022)
37 slides from Abcellera Biologics's investor presentation, May 13, 2022
Slide 1: Corporate Overview
CORPORATE OVERVIEW COPYRIGHT © ABCELLERA MAY 2022
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including These statements involve risks, uncertainties and other factors that may statements made pursuant to the safe harbor provisions of the Private cause actual results, levels of activity, performance, or achievements to be CORP
Slide 3: The Problem / Our Solution: Antibodies to Patients, Faster
THE PROBLEM OUR SOLUTION LIMITED TECHNOLOGIES & FRAGMENTED APPROACHES BRING BETTER CORPORATE OVERVIEW can’t keep pace with antibody next 50 antibodies took ANTIBODIES TO drug discovery. 6 years PATIENTS, FASTER. first 50 antibodies approved by FDA took We deliver lead candidates in 29 years less tim
Slide 4: We Had a Bold Vision: Best Capabilities from Target to IND
WE HAD A BOLD VISION TO BUILD THE BEST CAPABILITIES IN 2x faster THE WORLD FROM TARGET TO IND solve the unsolvable highest quality CORPORATE OVERVIEW unprecedented scale IND Engine TECHNOLOGY COMPOSITION OF MATTER Patentable DNA sequence of the drug TARGETS IND SPECIFICATIONS SOFTWARE + Investigatio
Slide 5: Where We Are Now
10 + YEARS OF EXPERTISE (founded in 2012) CORPORATE OVERVIEW WHERE WE ARE NOW ~$500M IN TECH DEVELOPMENT & ACQUISITIONS WE PROVIDE PARTNERS WITH 500K+ SQ.FT. OF FACILITIES (total lab, office, & manufacturing spaces by 2024) THE COMPETITIVE 400 EMPLOYEES + COPYRIGHT © ABCELLERA EDGE THEY NEED. 5
Slide 6: Where We're Going: Forward Integration to Accelerate Drug Development
WHERE WE’RE GOING FORWARD INTEGRATION TO ACCELERATE DRUG DEVELOPMENT. CORPORATE OVERVIEW AbCellera Development Partner Development 2012-2021: Antibody Discovery 2021-2024: Preclinical to IND Phase 1, 2, 3, Approval Tech Stack 1 2 3 4 5 Expansion into GMP / CMC Manufacturing SOURCE SEARCH DECODE ANAL
Slide 7: Partnering with the Best Drug Developers of All Sizes
D I S C L O S E D PA RT N E R S H I P S PARTNERING WITH THE BEST DRUG DEVELOPERS OF ALL SIZES. CORPORATE OVERVIEW We forge partnerships with large cap pharmaceutical companies, biotechnology companies of all sizes, and non-profit and government organizations through flexible deal structures: royalti
Slide 8: Illustrative Revenue Profile for One Successful Partnered Program
ILLUSTRATIVE REVENUE PROFILE FOR Key assumptions, hypothetical: $1.7 billion peak sales, no price inflation, no patient population growth, 5% royalty, 6 years to peak ONE SUCCESSFUL PARTNERED PROGRAM. sales, 5 years at peak sales, US approval only AbCellera participation in programs is strongly weig
Slide 9: COVID-19 Antibody Program
COVID-19 ANTIBODY PROGRAM. Similar revenue structure to typical program realized on a compressed timeline. royalties in aggregate of $526 million FULL YEAR 2021 BUSINESS UPDATE $250M (to Dec 31, 2021), over 95% of total program revenue $200M approval & commercial milestones $150M $14 million $100M c
Slide 10: Focused on Key Value Drivers
FOCUSSED ON KEY VALUE DRIVERS. FULL YEAR 2021 BUSINESS UPDATE Probability Speed Portfolio Deal of Success Volume Structures Capture downstream value maximize the likelihood superior returns superior that suitable leads without the volatility and biophysical properties. risks COPYRIGHT © ABCELLERA fa
Slide 11: Large Diversified Portfolio in Next-Gen Antibody Therapies
LARGE DIVERSIFIED 58% oncology PORTFOLIO 17% neurology IN NEXT-GEN 6% immunology CORPORATE OVERVIEW 6% ophthalmology ANTIBODY 5% infectious disease 3% dermatology THERAPIES. 50 % 5% other human health, known Portfolio of 131 programs n = 65 with downstream participation is diversified across the COP
Slide 12: Partners Look to Us to Unlock New Targets and Modalities
OUR PARTNERS LOOK TO US TO UNLOCK NEW TARGETS & NEXT-GEN MODALITIES 28% 72% CORPORATE OVERVIEW DIFFICULT targets STANDARD targets T ARG ET S multi-pass high homology peptide-MHC membrane targets targets targets radioisotope bispecific single domains IgGs, IgMs, IgAs conjugates antibodies (VHH) COPYR
Slide 13: Custom-Built Data Science Allows Scalable Integration with Computation & AI
CUSTOM-BUILT DATA SCIENCE ALLOWS SCALABLE INTEGRATION OF CUTTING-EDGE TECH WITH COMPUTATION & AI CORPORATE OVERVIEW Addressing the compounding data complexities of antibody discovery requires the following: 1 2 3 Proprietary technologies Proprietary data science Artificial intelligence and that can
Slide 14: Tech Stack: Make Every Step Count
T E C H STA C K MAKE EVERY STEP COUNT. Complex data integration driven by interlocking technologies optimizes each step with a compounding effect on the entire process. CORPORATE OVERVIEW 1 2 3 4 5 SOURCE SEARCH DECODE ANALYZE ENGINEER DELIVER immune responses millions of hundreds of hundreds to fin
Slide 15: Enabling Technologies
DATA ACCUMULATED CORPORATE OVERVIEW SOURCE SEARCH DECODE ANALYZE ENGINEER E N ABLI N G TE CH O LO G I E S Optimized High-Throughput Automated Customized Protein Engineering Immunization Single-Cell Single-Cell Bioinformatics, & Multispecifics Screening Genomics & High-Throughput Development from any
Slide 16: Leadership Team
LEADERSHIP TEAM TEAM IS EVERYTHING. Our founder-led team of 400+ employees includes engineers, data scientists, scientists, and business professionals. E X E CU TI V E S B O AR D O F D I R E C TO R S CORPORATE OVERVIEW Andrew Booth, MBA Neil Berkley, MBA, MS Carl Hansen, PhD Peter Thiel Michael Hayd
Slide 17: Financials: Strong Portfolio Growth
FINANCIALS Strong portfolio growth. Cumulative # of Cumulative # of Program Starts Molecules in the Clinic 84 6 CORPORATE OVERVIEW 90 6 80 Total # of 70 5 Programs Under Contract 158 60 4 50 3 40 Total # of 30 2 Discovery Partners 36 20 1 10 0 0 2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015
Slide 18: Molecules in the Clinic, Authorized for Emergency Use
FINANCIALS 6 molecules in the clinic, 2 authorized for emergency use. MOLECULE STAGE PARTNER THERAPEUTIC AREA PROGRAM TYPE bamlanivimab Marketed, Emergency Use • infectious disease – (LY-CoV555) Authorization (EUA) COVID-19 AbCellera Discovery CORPORATE OVERVIEW Partnership bebtelovimab Marketed, Em
Slide 19: Capital Efficient Growth as Basis for Ongoing Investment
FINANCIALS Capital efficient growth as basis for ongoing investment. Cash Flow USD FROM OPERATIONS EMPLOYEES 386 ~400 $245M $100M CORPORATE OVERVIEW $4M $3M $23M 206 107 55 FROM INVESTING 1 ($5M) ($6M) ($26M) CASH 2 , EQUIVALENTS & ($120M) ($85M) MARKETABLE SECURITIES USD FROM FINANCING $748M $811M
Slide 20: Tech Stack 01 Source: Optimized Immunization
TECH STACK 01 SOURCE COPYRIGHT © ABCELLERA OPTIMIZED IMMUNIZATION
Slide 21: Access the Database of Natural Antibodies
01 ACCESS THE DATABASE 1 SOURCE SEARCH DECODE ANALYZE ENGINEER OF NATURAL ANTIBODIES SOURCE. IMMUNIZATION OPTIMIZATION Natural immune systems contain a massively diverse database that encodes nature’s answers for fighting disease. This database can be used to develop the drugs of the future, but it’
Slide 22: Control Immunity to Generate Better Diversity
01 CONTROL IMMUNITY TO 1 SOURCE SEARCH DECODE ANALYZE ENGINEER GENERATE BETTER DIVERSITY SOURCE. IMMUNIZATION OPTIMIZATION We generate and access a high-quality universe of antibodies for any target. We trigger immune responses from any species with the goal proprietary any source human immunization
Slide 23: More Human Antibodies from Humanized Mice
01 MORE HUMAN ANTIBODIES, 1 SOURCE SEARCH DECODE ANALYZE ENGINEER FROM HUMANIZED MICE SOURCE. IMMUNIZATION OPTIMIZATION Source fully human antibodies from rodents to bypass the need to humanize sequences identified from non-humanized animals. With Flagship Mice: Diversity is our game. Integrated acc
Slide 24: Tech Stack 02 Search: High Throughput Single-Cell Screening
TECH STACK 02 SEARCH COPYRIGHT © ABCELLERA HIGH THROUGHPUT SINGLE-CELL SCREENING & FUNCTIONAL ASSAYS
Slide 25: Deeply Search Any Antibody Response with Microfluidic Single-Cell Assays
DEEPLY SEARCH ANY ANTIBODY RESPONSE WITH 2 02 SOURCE SEARCH DECODE ANALYZE ENGINEER MICROFLUIDIC SINGLE-CELL ASSAYS SEARCH. SINGLE-CELL SCREENING Multiple credit card-sized devices integrating hundreds of thousands of miniaturized chambers per device to <1 nL single-cell chamber screen millions of B
Slide 26: Search for Any Antibody Property
SEARCH FOR ANY ANTIBODY PROPERTY 2 02 SOURCE SEARCH DECODE ANALYZE ENGINEER SEARCH. HIGH-THROUGHPUT SINGLE-CELL SCREENING AFFINITY LIGAND-BINDING SPECIFITY & CROSS-REACTIVITY LIVE-CELL COMBINATION COPYRIGHT © ABCELLERA 26
Slide 27: Tech Stack 03 Decode: Automated Single-Cell Genomics
TECH STACK 03 DECODE COPYRIGHT © ABCELLERA AUTOMATED SINGLE-CELL GENOMICS & REPERTOIRE PROFILING
Slide 28: Amplify Lead Candidates with Repertoire Sequencing
AMPLIFY LEAD CANDIDATES 3 03 SOURCE SEARCH DECODE ANALYZE ENGINEER WITH REPERTOIRE SEQUENCING DECODE. REPERTOIRE SEQUENCING 1 2 3 4 START FROM SEARCH DECODE ANALYZE EXPRESS, CHARACTERIZE, VALIDATE SELECT new antibody pairs in parallel iterative 2 5 SEQUENCE MAP, ANNOTATE, PAIR COPYRIGHT © ABCELLERA
Slide 29: Amplify Options from a Single-Cell Lead Through Repertoire Sequence Mapping
3 SIN G LE - CE LL LE A D L I N E A G E T R E E A D D ITION A L LE A D S L I N E A G E T R E E 03 SOURCE SEARCH DECODE ANALYZE ENGINEER G G DECODE. REPERTOIRE SEQUENCING S I AMPLIFY OPTIONS FROM A SINGLE-CELL LEAD S I I I I THROUGH S S R R R I S S REPERTOIRE S I I I SEQUENCE R I R I I I MAPPING R SR
Slide 30: Tech Stack 04 Analyze: Customized Bioinformatics and Expression
TECH STACK 04 ANALYZE CUSTOMIZED BIOINFORMATICS, COPYRIGHT © ABCELLERA HIGH-THROUGHPUT EXPRESSION & BIOANALYTICS
Slide 31: See the Big Picture with Meaningful Data
4 04 SEE THE BIG PICTURE WITH SOURCE SEARCH ANALYZE ENGINEER MEANINGFUL DATA. ANALYZE. BIOINFORMATICS & VISUALIZATION Grasp the complexity of large single cell antibody datasets. Celium™, our proprietary software brings data to life. Designed to visually explore data, interrogate every parameter, he
Slide 32: Select the Best, of the Best
4 04 SELECT THE BEST, OF THE BEST. SOURCE SEARCH ANALYZE ENGINEER ANALYZE. BIOINFORMATICS & VISUALIZATION Use developability HIGH-THROUGHPUT EXPRESSION BINDING VALIDATION FUNCTIONAL VALIDATION EPITOPE BINNING information to help select your best leads. Validate hundreds of antibodies with high-throu
Slide 33: Tech Stack 05 Engineer: Protein Engineering & Multispecifics
TECH STACK 05 ENGINEER COPYRIGHT © ABCELLERA PROTEIN ENGINEERING & MULTISPECIFICS DEVELOPMENT
Slide 34: Combine Any Two Antibodies to Create Native Bispecifics
5 05 COMBINE ANY TWO ANTIBODIES TO SOURCE SEARCH ENGINEER CREATE NATIVE BISPECIFICS. ENGINEER. EXPRESSION & BIOANALYTICS STAN D AR D PAR E N TAL I g G ’ s mutation mutation Example mutations 3 protein-protein interfaces at a heavy-light A C with 1 to 4 mutations per chain (Fab) VH domain to ensure c
Slide 35: Improve Development of Bispecifics with a Clinically-Validated Platform
5 05 IMPROVE DEVELOPMENT OF BISPECIFICS SOURCE SEARCH ENGINEER WITH A CLINICALLY-VALIDATED PLATFORM. ENGINEER. EXPRESSION & BIOANALYTICS Faster development with native IgG-like format. Diverse panels. Stable + manufacturable. Proven platform. • Optimized discovery yields • Standardized mAb protocols
Slide 36: Engineer Fit-for-Purpose Lead Antibody Candidates
5 05 ENGINEER FIT-FOR-PURPOSE SOURCE SEARCH ENGINEER LEAD ANTIBODY CANDIDATES. ENGINEER. EXPRESSION & BIOANALYTICS Our protein engineering tool-kit supports next-generation antibody therapeutics, such as VHH constructs, humanization, deimmunization, optimization, reformatting, and most recently, bis
Slide 37: AbCellera Investor Relations
ABCELLERA INVESTOR RELATIONS IR@ABCELLERA.COM COPYRIGHT © ABCELLERA 37
AbCellera Biologics — Investor Presentation (May 2022) on 6ix